#United States #New Orleans #glaucoma #Avisi Technologies #VisiPlate®

Avisi Technologies Highlights Groundbreaking VitiPlate® Data at AAO Annual Meeting

Avisi Technologies, Inc., a pioneering company in ophthalmic medical devices, is set to make waves at the upcoming 2026 American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, LA. Scheduled for October 10th, the company will showcase significant follow-up data from the VITA clinical trial—an innovative study focused on their patented VisiPlate® Aqueous Shunt.

The VITA Trial Overview

The VITA trial is a pivotal, prospective, single-arm, multi-center, open-label clinical study carried out across three sites in South Africa. It primarily evaluated the long-term efficacy and safety of the ultrathin, multichannel aqueous shunt designed for patients suffering from primary open-angle glaucoma (OAG). Dr. Jonathan S. Myers, a renowned expert and Director of the Wills Eye Hospital Glaucoma Service, will be presenting the trial's findings during a poster session on October 11, from 3:30 PM to 4:30 PM CST at the AAO poster theater.

Presentation Highlights

On the previous day, October 10, Avisi will host two additional presentations at Booth #1255. The first session, titled “Vita Trial 2-Year Data,” will occur from 2 PM to 3 PM, followed by a second presentation discussing “VisiPlate Design Surgical Pearls” from 4 PM to 5 PM. Dr. Myers will lead the discussions on the trial’s long-term follow-up data, sharing crucial insights with fellow researchers and clinical professionals.

A distinguished panel, which includes Dr. Eydie Miller-Ellis, President of the American Glaucoma Society, and Dr. Joseph Panarelli of NYC Retina, will join Dr. Myers for the second session. This engaging conversation will be moderated by Sanjeev Kasthurirangan, PhD, and will cover the design, technology, and practical insights gleaned from the ongoing FDA IDE trial involving VisiPlate®.

VisiPlate® Aqueous Shunt: A Game-Changer

Avisi's VisiPlate® Aqueous Shunt is a transformative device utilized in glaucoma surgeries. Crafted from a unique patented metamaterial, it is designed to be non-fibrotic and remarkably thinner than a human hair. The shunt features multiple microchannels, engineered to ensure continuous aqueous flow while minimizing the risks associated with blockage and the need for re-interventions—common complications found in traditional glaucoma treatments.

Understanding Glaucoma

Glaucoma stands as the leading cause of irreversible blindness globally, affecting approximately 133 million individuals, according to Market Scope’s 2025 report on glaucoma surgical devices. With the condition characterized by increased ocular pressure damaging the optic nerve, it often manifests silently, making early detection and continuous management critical. Current treatment options encompass a range of medical therapies, surgical interventions, and newer device solutions. However, most of these methods rely heavily on patient adherence and can fail due to factors like occlusion and fibrotic reactions over time.

The Future of Glaucoma Treatment

The ongoing challenges and need for effective long-term solutions to manage glaucoma underscore the importance of studies like the VITA trial. Avisi Technologies remains at the forefront of innovation in ophthalmic care, striving to improve outcomes and enhance the quality of life for those battling vision impairment from glaucoma. As it looks forward to sharing its findings at the AAO conference, the company continues to garner recognition and support from organizations such as the National Science Foundation, Glaucoma Research Foundation, and others.

For more information about Avisi Technologies and its pioneering products, visit avisitech.com.

Conclusion

With the anticipated presentation of the VitiPlate® data at the AAO Annual Meeting, Avisi Technologies stands poised to make a significant impact in the field of ophthalmology, offering hope and innovative solutions for glaucoma patients worldwide. This event marks a vital moment where science converges with technology to tackle one of the most pressing challenges in eye care today.